Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Streaming Portfolio Company Safety Strips, Provides Corporate Update (click to learn more) Saturn Oil & Gas Inc. Announces $525 Million Accretive Core-Area Saskatchewan Asset Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CanaQuest Medical Corp CANQF

Biotechnology
CanaQuest Medical Corporation is a Canada-based clinical-stage, life sciences company. The Company is focused on the drug discovery and development of targeted therapeutics within the endocannabinoid system and specific brain receptors. The Company is also focused on treating neurological conditions, such as epilepsy, anxiety, depression, and Post Traumatic Stress Disorder (PTSD), including addiction. It provides a novel master formulation derived from cannabidiol (CBD) + IP formula. The Company has a drug candidate, CQ-001, which is positioned for clinical trials, targeting epilepsy. An OTC version of the master formulation, branded as Mentanine, is available for sale via the Company’s store in the United States. Its non-psychoactive properties provide a safe and effective alternative to traditional treatments with minimal effects. The Company’s wholly owned subsidiary is ADC BioMedical Corp.


OTCPK:CANQF - Post by User

CanaQuest Medical Corp
Bullboard Posts
User Avatar Image
(42)
•••
Post by thedave2006on Feb 06, 2019 9:57am
35 Views
Post# 29325394

cannabis properties from algae

cannabis properties from algaemmmmmm
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities